secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2024-12-06T23:59:59+00:00
Accession:  0001213900-24-106240
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CERo Therapeutics appoints Chris Ehrlich as permanent CEO
---------------------------------------------------------

- Chris Ehrlich appointed permanent CEO effective Dec 2, 2024, was interim since Oct 2.
- Company plans to file IND for CER-1236 in solid tumors (ovarian, NSCLC) in H1 2025.
- Ehrlich also serves as CEO of Launch One Acquisition Corp.
- Ehrlich brings biotech leadership experience including prior SPAC mergers and venture capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024106240/0001213900-24-106240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024106240/ea0223559-8k_cerotherap.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-106240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer